Search…

Tiantan Bio (600161.SH) subsidiary company receives clinical trial summary report.

04/12/2025

CapitalEye Financial News APP: Tiens Group (600161.SH) has announced that recently, the "Human Prothrombin Complex" developed by its subsidiary, Guizhou Biopharmaceutical Co., Ltd. (referred to as "Tiens Guizhou"), has completed Phase III clinical trials and obtained the clinical trial summary report.

Latest

2 m ago

According to the AI Express of Every Capital, First Shanghai Securities issued a research report on December 4th, giving Cambricon Technologies (688256.SH) a "buy" rating. The main reasons for the rating include: 1) Accelerated landing of AI applications, with positive outlook for demand from major customers; 2) Acceleration of domestic computing power substitution, with an urgent need to alleviate supply-demand gap. (Daily Economic News)

3 m ago

China Everbright (01359.HK): Wang Kunhui Nominated as Non-Executive Director

3 m ago

According to the Japanese news agency Jiji Press, the Bank of Japan is evaluating the neutral interest rate level.

4 m ago

Bank of England: The list of participating institutions and scenario details will be published in 2026, with the final report set to be released in 2027.

5 m ago

Chongqing Water Affairs: Intends to acquire a sewage treatment project for 255 million RMB.

See all latest